



CORRECTION

Open Access



Correction: Exploring the prognostic significance of blood carnitine and acylcarnitines in hepatitis C virus-induced hepatocellular carcinoma

Ashraf Abbass Basuni¹, Azza El Sheashaey³, Ashraf El Fert¹, Manar Obada¹, Eman Abdelsameea², Mohamed Abdel-Samiee², Asmaa Ibrahim² and Ashraf Khalil^{1*}

Correction: Egypt Liver J 14, 19 (2024)
<https://doi.org/10.1186/s43066-024-00322-x>

Following publication of the original article [1], the following corrections have been made to this published article.

1. Corrections to the names of the first and fifth authors.

“Ashraf Abbass” has been corrected to “Ashraf Abbass Basuni”.

“Mohammed” of Mohamed Abdel-Samiee has been corrected to “Mohamed”.

2. Rectification of the reference section (Incorrect placement of the publication year): The following reference entries have been amended to move the year of publication at the of authors’ names instead of appearing in the middle of the authors’ names.

[7] Fitian AI, DR Nelson, C Liu, Y Xu, M Araratand R Cabrera (2014) Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. *Liver Int* 34(9):1428–1444

[9] Koppenol WH, PL Boundsand, CV Dang (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. *Nat Rev Cancer* 11(5):325–337

[10] Longo N, M Frigeniand M Pasquali (2016) Carnitine transport and fatty acid oxidation. *Biochim Biophys Acta* 1863(10):2422–2435

[11] Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, RH Weiss (2012) Urinary acylcarnitines are altered in human kidney cancer. *Int J Cancer* 130(12):2791–800

[15] Violante S, L Ijlst, H Te Brinke, I Tavares de Almeida, RJ Wanders, FV Venturaand SM Houten (2013) Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. *FASEB J* 27(5):2039–2044.

[17] Ni J, L Xu, W Li, C Zhengand L Wu (2019) Targeted metabolomics for serum amino acids and acylcarnitines in patients with lung cancer. *Exp Ther Med* 18(1):188–198

[18] Sun C, F Wang, Y Zhang, J Yuand X Wang (2020) Mass spectrometry imaging-based metabolomics to visualize the spatially resolved reprogramming of carnitine metabolism in breast cancer. *Theranostics* 10(16):7070–7082

[20] Pugh RN, IM Murray-Lyon, JL Dawson, MC Pietroniand R Williams (1973) Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 60(8):646–649

[21] Smith A, K Baumgartnerand C Bosisit (2019) Cirrhosis: diagnosis and management. *Am Fam Physician* 100(12):759–770

[23] de Freitas LBR, L Longo, D Santos, I Grivicichand MR Alvares-da-Silva (2019) Hepatocellular carcinoma

The original article can be found online at <https://doi.org/10.1186/s43066-024-00322-x>.

*Correspondence:

Ashraf Khalil
ashkhalil2010@gmail.com

¹ Department of Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shibin El Kom, Egypt

² Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shibin El Kom, Egypt

³ Department of Zoology, Faculty of Science, Menoufia University, Shibin El Kom, Egypt



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

staging systems: Hong Kong liver cancer vs Barcelona Clinic Liver Cancer in a Western population. *World J Hepatol* 11(9):678–688

[29] Miyaaki H, H Kobayashi, S Miuma, M Fukusima, R Sasaki, M Haraguchi and K Nakao (2020) Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients. *BMC Gastroenterol* 20(1):41

[30] Shibahara J, S Ando, Y Sakamoto, N Kokudo and M Fukayama (2014) Hepatocellular carcinoma with

steatohepatic features: a clinicopathological study of Japanese patients. *Histopathology* 64(7):951–962

[34] Zhang Y, N Ding, Y Cao, Z Zhu and P Gao (2018) Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines. *Int J Clin Exp Pathol* 11(3):1763–1769

3. Adjustment to Table 1: The 7th column labeled “M ± SD” has been moved two spaces to the left next to the 4th column Med (IQR).

Old version of Table 1:

Table 1 Clinical and laboratory characteristics of the studied groups

		HCC, n=90		HCV, n=55		Con, n=25				P < 0.05
Age	M ± SD	58.8(7.5)	50.9(8.)			51.9(7.2)				a
Sex	Female	12 (13.3%)	32 (58.2%)			13 (52%)				a
	Male	78 (86.7%)	23 (41.8%)			12 (48%)				a
BMI	M ± SD	27.5(3.6)	27.3(3.7)			27.7(3.6)				NS
Liver size	WNS	73 (81.1%)	38 (69.1%)			25 (100%)				
	Enlarged	13 (14.4%)	17 (30.9%)			0.0(0%)				0.001
	Shrunken	4 (4.4%)								
Splenomegaly	No	27 (30%)	31 (56.4%)			25 (100%)				
	Yes	63 (70%)	24 (43.6%)			0 (0%)				0.001
Liver cirrhosis	No	0 (0%)	7 (12.7%)			25 (100%)				
	Yes	90 (100%)	48 (87.3%)			0 (0%)				
Ascites	No	67 (74.4%)	55 (100%)			25 (100%)				
	Mild	17 (18.9%)								
	Mod	6 (6.7%)								
HFL	Multiple	52 (57.8%)	0 (0%)			0 (0%)				
	Single	38 (42.2%)	0 (0%)			0 (0%)				0.001
CPC	A	64 (71.1%)	40 (72.7%)							
	B	21 (23.3%)	11 (20%)							
	C	5 (5.6%)	4 (7.3%)							
BCLC	A	25 (27.8%)								
	B	48 (53.3%)								
	C	12 (13.3%)								
	D	5 (5.6%)								
Laboratory	MSD	Min–Max	Med (IQR)	Min–Max	Med (IQR)	MSD	MSD	Min–Max	Med (IQR)	P < 0.05
ALT	59.49 ± 29.15	17–168	53.5 (23.5)	12–221	37 (46)	50.49 ± 37.98	31.24 ± 23.17	10–113	23 (26.5)	a, b, c
AST	61.80 ± 28.95	9–174	55.5 (27.5)	6–166	36 (28)	45.69 ± 29.65	31.80 ± 16.09	11–64	30 (20.5)	a, b, c
Albumin	3.61 ± 0.59	2.3–4.8	3.7 (1)	3.8–4.8	4.1 (0.5)	4.17 ± 0.29	4.26 ± 0.73	2.3–5.2	4.4 (1)	a, c
T.Bil	1.06 ± 0.61	0.2–3.2	0.9 (0.5025)	0.3–1.5	0.56 (0.28)	0.61 ± 0.27	0.83 ± 0.22	0.4–1.2	0.9 (0.4)	NS
D.Bil	0.45 ± 0.33	0.1–2	0.38 (0.4)	0.1–0.9	0.2 (0.16)	0.24 ± 0.15	0.14 ± 0.06	0.01–0.28	0.13 (0.045)	a, b, c
Creatinine	0.91 ± 0.21	0.4–1.5	0.9 (0.2175)	0.4–1.45	0.71 (0.2)	0.72 ± 0.19	1.08 ± 0.38	0.6–1.9	1.1 (0.605)	b, c
AFP	709 ± 3140	1.39–27,850	86.7 (256.45)	0.9–182.2	3 (3.6)	11.90 ± 30.95	3.28 ± 2.19	1.1–11	2.9 (1.015)	a, c
Hb	13.41 ± 1.74	8.7–16.4	13.6 (2.4)	9.3–17.3	14 (1.9)	14.02 ± 1.60	12.67 ± 1.47	9–15.4	13.2 (2.15)	a, b, c
WBC	5.78 ± 1.72	2–9.6	5.35 (2.6)	3.2–12.7	6.6 (3.3)	7.12 ± 2.08	7.55 ± 4.65	3.1–19.8	6.2 (4.15)	c
Platelet	146.93 ± 57.29	55–331	141 (67.75)	71–438	242 (108)	235.44 ± 74.29	204.44 ± 53.86	132–320	192 (97.5)	a, c
PT%	80.24 ± 12.69	36–106	82 (14.75)	57.8–100	94 (17)	90.38 ± 10.70	95.76 ± 5.95	80–100	98 (8)	a, b, c
INR	1.19 ± 0.17	0.97–1.9	1.135 (0.15)	1–1.39	1.04 (0.14)	1.08 ± 0.10	1.08 ± 0.08	1–1.3	1.06 (0.095)	a, c

HCC hepatocellular carcinoma, HCV hepatitis C virus, Con normal control, Med median, Interquartile range (IQR). Mean ± SD: mean ± standard deviation. Significance P value < 0.05 is present when Kruskal Wallance and pairwise tests (Mann Whitney U) are performed across the group. a = p < 0.05 when comparing HCC vs. Con. b = p < 0.05 when comparing HCV vs. Con. c = p < 0.05 when comparing HCC vs. HCV, BMI body mass index, CPS Child–Pugh class, HFL hepatic focal lesion, BCLC Barcelona clinic liver cancer (BCLC) staging. AST aspartate transaminase, ALT alanine transaminase, TBil total bilirubin, DBil direct bilirubin, AFP alpha phetoprotein. Hb hemoglobin, WBCs white blood cells, PT prothrombin time, INR international normalized ratio

New/corrected version of Table 1:

Table 1 Clinical and laboratory characteristics of the studied groups

		HCC, n = 90			HCV, n = 55			Con, n = 25			P < 0.05
Age	M ± SD	58.8(7.5)		50.9(8.)				51.(7.2)			a
Sex	Female	12 (13.3%)		32 (58.2%)				13 (52%)			a
	Male	78 (86.7%)		23 (41.8%)				12 (48%)			a
BMI	M ± SD	27.5(3.6)		27.3(3.7)				27.7(3.6)			NS
Liver size	WNS	73 (81.1%)		38 (69.1%)				25 (100%)			
	Enlarged	13 (14.4%)		17 (30.9%)				0.0(0%)			0.001
	Shrunken	4 (4.4%)									
Splenomegaly	No	27 (30%)		31 (56.4%)				25 (100%)			
	Yes	63 (70%)		24 (43.6%)				0 (0%)			
Liver cirrhosis	No	0 (0%)		7 (12.7%)				25 (100%)			0.001
	Yes	90 (100%)		48 (87.3%)				0 (0%)			
Ascites	No	67 (74.4%)		55 (100%)				25 (100%)			
	Mild	17 (18.9%)									
	Mod	6 (6.7%)									
HFL	Multiple	52 (57.8%)		0 (0%)				0 (0%)			
	Single	38 (42.2%)		0 (0%)				0 (0%)			0.001
CPC	A	64 (71.1%)		40 (72.7%)							
	B	21 (23.3%)		11 (20%)							
	C	5 (5.6%)		4 (7.3%)							
BCLC	A	25 (27.8%)									
	B	48 (53.3%)									
	C	12 (13.3%)									
	D	5 (5.6%)									
Laboratory	M ± SD	Min–Max	Med (IQR)	M ± SD	Min–Max	Med (IQR)	M ± SD	Min–Max	Med (IQR)	P < 0.05	
ALT	59.49 ± 29.15	17–168	53.5 (23.5)	50.49 ± 37.98	12–221	37 (46)	31.24 ± 23.17	10–113	23 (26.5)	a, b, c	
AST	61.80 ± 28.95	9–174	55.5 (27.5)	45.69 ± 29.65	6–166	36 (28)	31.80 ± 16.09	11–64	30 (20.5)	a, b, c	
Albumin	3.61 ± 0.59	2.3–4.8	3.7 (1)	4.17 ± 0.29	3.8–4.8	4.1 (0.5)	4.26 ± 0.73	2.3–5.2	4.4 (1)	a, c	
T.Bil	1.06 ± 0.61	0.2–3.2	0.9 (0.5025)	0.61 ± 0.27	0.3–1.5	0.56 (0.28)	0.83 ± 0.22	0.4–1.2	0.9 (0.4)	NS	
D.Bil	0.45 ± 0.33	0.1–2	0.38 (0.4)	0.24 ± 0.15	0.1–0.9	0.2 (0.16)	0.14 ± 0.06	0.01–0.28	0.13 (0.045)	a, b, c	
Creatinine	0.91 ± 0.21	0.4–1.5	0.9 (0.2175)	0.72 ± 0.19	0.4–1.45	0.71 (0.2)	1.08 ± 0.38	0.6–1.9	1.1 (0.605)	b, c	
AFP	709 ± 3140	1.39–27,850	86.7 (256.45)	11.90 ± 30.95	0.9–182.2	3 (3.6)	3.28 ± 2.19	1.1–11	2.9 (1.015)	a, c	
Hb	13.41 ± 1.74	8.7–16.4	13.6 (2.4)	14.02 ± 1.60	9.3–17.3	14 (1.9)	12.67 ± 1.47	9–15.4	13.2 (2.15)	a, b, c	
WBC	5.78 ± 1.72	2–9.6	5.35 (2.6)	7.12 ± 2.08	3.2–12.7	6.6 (3.3)	7.55 ± 4.65	3.1–19.8	6.2 (4.15)	c	
Platelet	146.93 ± 57.29	55–331	141 (67.75)	235.44 ± 74.29	71–438	242 (108)	204.44 ± 53.86	132–320	192 (97.5)	a, c	
PT%	80.24 ± 12.69	36–106	82 (14.75)	90.38 ± 10.70	57.8–100	94 (17)	95.76 ± 5.95	80–100	98 (8)	a, b, c	
INR	1.19 ± 0.17	0.97–1.9	1.135 (0.15)	1.08 ± 0.10	1–1.39	1.04 (0.14)	1.08 ± 0.08	1–1.3	1.06 (0.095)	a, c	

HCC hepatocellular carcinoma, HCV hepatitis C virus, Con normal control, Med median, Interquartile range (IQR). Mean ± SD: mean ± standard deviation. Significance P value < 0.05 is present when Kruskal Wallance and pairwise tests (Mann Whitney U) are performed across the group. a = p < 0.05 when comparing HCC vs. Con. b = p < 0.05 when comparing HCV vs. Con. c = p < 0.05 when comparing HCC vs. HCV, BMI body mass index, CPS Child–Pugh class, HFL hepatic focal lesion, BCLC Barcelona clinic liver cancer (BCLC) staging. AST aspartate transaminase, ALT alanine transaminase, TBil total bilirubin, DBil direct bilirubin, AFP alpha fetoprotein. Hb hemoglobin, WBCs white blood cells, PT prothrombin time, INR international normalized ratio

The original article [1] has been corrected.

Published online: 06 July 2024

Reference

1. Basuni AA, Sheashaey AE, Fert AE et al (2024) Exploring the prognostic significance of blood carnitine and acylcarnitines in hepatitis C virus-induced hepatocellular carcinoma. *Egypt Liver Journal* 14:19. <https://doi.org/10.1186/s43066-024-00322-x>